Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.55 USD
-0.83 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $46.57 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -352.09 | -231.80 | 1,604.72 | -327.37 | -411.47 |
Depreciation/Amortization & Depletion | 1.57 | 7.37 | 16.19 | 13.01 | 4.89 |
Net Change from Assets/Liabilities | -19.06 | -16.43 | -36.82 | -71.04 | -46.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | -2,054.46 | 0.00 | 0.00 |
Other Operating Activities | 73.51 | -68.61 | 63.06 | 94.64 | 81.96 |
Net Cash From Operating Activities | -296.06 | -309.48 | -407.32 | -290.76 | -370.62 |
Property & Equipment | 0.33 | -3.92 | -5.74 | -14.91 | -12.17 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 256.75 | 115.39 | -548.42 | 90.65 | 103.61 |
Other Investing Activities | -17.50 | 131.78 | 1,802.94 | 0.00 | 0.00 |
Net Cash from Investing Activities | 239.58 | 243.26 | 1,248.78 | 75.75 | 91.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.43 | 2.68 | -765.19 | 11.32 | 289.72 |
Issuance (Repayment) of Debt | 0.00 | -0.33 | -0.58 | -0.34 | -0.11 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 250.54 | 0.00 |
Net Cash from Financing Activities | 5.43 | 2.35 | -765.77 | 261.52 | 289.61 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -51.05 | -63.87 | 75.69 | 46.51 | 10.43 |
Cash at Beginning of Period | 139.26 | 203.13 | 127.44 | 80.93 | 70.50 |
Cash at End of Period | 88.21 | 139.26 | 203.13 | 127.44 | 80.93 |
Diluted Net EPS | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 |
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -177.67 | -81.55 | -352.09 | -256.15 | -164.82 |
Depreciation/Amortization & Depletion | -2.20 | -1.18 | 1.57 | 0.56 | -2.14 |
Net Change from Assets/Liabilities | -18.86 | -28.99 | -19.06 | -24.66 | -21.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 26.27 | 11.85 | 73.51 | 56.67 | 26.99 |
Net Cash From Operating Activities | -172.46 | -99.87 | -296.06 | -223.57 | -161.93 |
Property & Equipment | -0.26 | -0.10 | 0.33 | 0.56 | -0.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 162.07 | 124.66 | 256.75 | 161.00 | 104.97 |
Other Investing Activities | 0.00 | 0.00 | -17.50 | -17.50 | 0.00 |
Net Cash from Investing Activities | 161.81 | 124.56 | 239.58 | 144.06 | 104.72 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.96 | 5.86 | 5.43 | 4.59 | 2.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 6.96 | 5.86 | 5.43 | 4.59 | 2.70 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -3.69 | 30.56 | -51.05 | -74.93 | -54.51 |
Cash at Beginning of Period | 88.21 | 88.21 | 139.26 | 139.26 | 139.26 |
Cash at End of Period | 84.52 | 118.76 | 88.21 | 64.33 | 84.75 |
Diluted Net EPS | -1.69 | -1.45 | -1.71 | -1.64 | -1.51 |